CSIMarket
 


Cel sci Corporation  (CVM)
Other Ticker:  
 
 

CVM's Capital Expenditures Growth by Quarter and Year

Cel Sci's Capital Expenditures results by quarter and year




CVM Capital Expenditures (in millions $) FY 2024 FY 2023 FY 2022 FY 2021
IV Quarter September - 0.01 0.66 0.41
III Quarter June - 0.20 0.00 2.00
II Quarter March - 0.11 0.53 3.48
I Quarter December 0.06 0.05 0.04 3.15
FY   0.06 0.37 1.23 9.04



CVM Capital Expenditures first quarter 2024 Y/Y Growth Comment
Cel sci Corporation reported Capital Expenditures improvement of 29.72% year on year in the first quarter 2024, to $ 0.06 millions, this is lower than Cel Sci Corporation's recent average Capital Expenditures surge of 3487.33%.

Looking into first quarter 2024 results within Biotechnology & Pharmaceuticals industry 4 other companies have achieved higher Capital Expenditures growth. While Cel Sci Corporation' s Capital Expenditures rise of 29.72% ranks overall at the positon no. 223 in the first quarter 2024.




CVM Capital Expenditures ( Y/Y Growth %) 2024
2023 2022 2021
IV Quarter September - -98.48 % 60.98 % -63.39 %
III Quarter June - - - 150 %
II Quarter March - -79.25 % -84.77 % 435.38 %
I Quarter December 29.72 % 25 % -98.73 % 2763.64 %
FY   - -69.92 % -86.39 % 237.31 %

Financial Statements
Cel Sci's first quarter 2024 Capital Expenditures $ 0.06 millions CVM's Income Statement
Cel Sci's first quarter 2023 Capital Expenditures $ 0.05 millions Quarterly CVM's Income Statement
New: More CVM's historic Capital Expenditures Growth >>


CVM Capital Expenditures (Quarter on Quarter Growth %)

2024
2023 2022 2021
IV Quarter September - -95 % - -79.5 %
III Quarter June - 81.82 % - -42.53 %
II Quarter March - 120 % 1225 % 10.48 %
I Quarter December 548.61 % -92.42 % -90.24 % 181.25 %
FY (Year on Year)   - -69.92 % -86.39 % 237.31 %




Capital Expenditures first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #26
Overall #223

Capital Expenditures Y/Y Growth Statistics
High Average Low
101405.19 % 3487.33 % -100 %
(Mar 31 2019)   (Jun 30 2022)
Capital Expenditures first quarter 2024 Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #5
Healthcare Sector #26
Overall #223
Capital Expenditures Y/Y Growth Statistics
High Average Low
101405.19 % 3487.33 % -100 %
(Mar 31 2019)   (Jun 30 2022)

Capital Expenditures by Quarter for the Fiscal Years 2021, 2022, 2023, 2024

Cel Sci's Q/Q Capital Expenditures Growth


Capital Expenditures Q/Q Growth Statistics
High Average Low
2238.09 % 170.62 % -100 %
(Sep 30 2018)  


CVM's I. Quarter Q/Q Capital Expenditures Comment
Cel sci Corporation achieved in the I. Quarter 2024 above company average sequential Capital Expenditures doubling of 548.61%, to $ 0.06 millions, from $0.01 millions in the fourth quarter.
Biotechnology & Pharmaceuticals company is going from strength to strength, not only reporting better then regular growth, and additionally increasing pace, Marc Álvarez, Healthcare sector contributor added.

Within Biotechnology & Pharmaceuticals industry Cel sci Corporation achieved highest sequential Capital Expenditures growth. While Cel Sci's Capital Expenditures growth quarter on quarter, overall rank is 21.


Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #1
Healthcare Sector #2
Overall #21
Capital Expenditures Q/Q Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry #1
Healthcare Sector #2
Overall #21
Capital Expenditures Q/Q Growth Statistics
High Average Low
2238.09 % 170.62 % -100 %
(Sep 30 2018)  


CVM's I. Quarter Q/Q Capital Expenditures Comment
Cel sci Corporation achieved in the I. Quarter 2024 above company average sequential Capital Expenditures doubling of 548.61%, to $ 0.06 millions, from $0.01 millions in the fourth quarter.
Biotechnology & Pharmaceuticals company is impressively improving, with recording better then regular increase, but also improving rate.

Within Biotechnology & Pharmaceuticals industry Cel sci Corporation achieved highest sequential Capital Expenditures growth. While Cel Sci's Capital Expenditures growth quarter on quarter, overall rank is 21.


Cel Sci's 12 Months Capital Expenditures Growth Year on Year


Capital Expenditures TTM Growth

12 Months Ending
(Dec 31 2023)
12 Months Ending
(Sep 30 2023)
12 Months Ending
(Jun 30 2023)
12 Months Ending
(Mar 31 2023)
12 Months Ending
(Dec 31 2022)
Cumulative Capital Expenditures 12 Months Ending $ 0.38 $ 0.37 $ 1.02 $ 0.00 $ 0.67
Y / Y Capital Expenditures Growth (TTM) - - - - -88.62 %
Year on Year Capital Expenditures Growth Overall Ranking # 536 # 2445 # 1800 # 1866 # 1554
Seqeuential Capital Expenditures Change (TTM) 3.03 % -63.59 % - - 2.09 %
Seq. Capital Expenditures Growth (TTM) Overall Ranking # 295 # 431 # 1785 # 1785 # 2096




Cumulative Capital Expenditures growth Comment
Although Cel Sci's Annual Capital Expenditures growth year on year were below company's average 532.42% , Capital Expenditures announced in the Dec 31 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 29.72% year on year, from % in Sep 30 2023.

In the Healthcare sector 56 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 536, from total ranking in previous quarter at 2445.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
3339.27 %
532.42 %
-95.79 %
 

Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 4
Healthcare Sector # 57
Overall # 536

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
3339.27 %
532.42 %
-95.79 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 25
S&P 500 # 295
Cumulative Capital Expenditures growth Comment
Although Cel Sci's Annual Capital Expenditures growth year on year were below company's average 532.42% , Capital Expenditures announced in the Dec 31 2023 period, show improvement in Capital Expenditures trend, to cumulative trailing twelve month growth of 29.72% year on year, from % in Sep 30 2023.

In the Healthcare sector 56 other companies have achieved higher trailing twelve month Capital Expenditures growth. While Total ranking has impoved so far to 536, from total ranking in previous quarter at 2445.

Capital Expenditures TTM Q/Q Growth Statistics
High Average Low
3339.27 %
532.42 %
-95.79 %
 


Capital Expenditures TTM Y/Y Growth Company Ranking
Within: No.
Biotechnology & Pharmaceuticals Industry # 4
Healthcare Sector # 57
Overall # 536

Capital Expenditures TTM Y/Y Growth Statistics
High Average Low
3339.27 %
532.42 %
-95.79 %
 


Capital Expenditures TTM Q/Q Growth Company Ranking
Within: No.
Industry # 4
Sector # 25
S&P 500 # 295




Other Capital Expenditures Growth
Biotechnology & Pharmaceuticals Industry Capital Expenditures Growth Trends and Statistics
Healthcare Sector Capital Expenditures Growth Statistics
Capital Expenditures Growth Trends for overall market
CVM's Capital Expenditures Growth Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and total Market
Highest Ranking Capital Expenditures Growth
Lowest Ranking Capital Expenditures Growth
Capital Expenditures Growth for CVM's Competitors
Capital Expenditures Growth for Cel Sci's Suppliers
Capital Expenditures Growth for CVM's Customers

You may also want to know
CVM's Annual Growth Rates CVM's Profitability Ratios CVM's Asset Turnover Ratio CVM's Dividend Growth
CVM's Roe CVM's Valuation Ratios CVM's Financial Strength Ratios CVM's Dividend Payout Ratio
CVM's Roa CVM's Inventory Turnover Ratio CVM's Growth Rates CVM's Dividend Comparisons



Companies with similar Capital Expenditures doubling for the quarter ending Dec 31 2023 within Healthcare SectorY/Y Change %Capital Expenditures for the quarter ending Dec 31 2023
Avantor Inc 50.60%$ 50.595 millions
Bausch Health Companies Inc 50.00%$ 50.000 millions
Gh Research Plc49.25%$ 49.254 millions
Cryoport inc 44.64%$ 44.636 millions
Hologic Inc43.67%$ 43.671 millions
Viemed Healthcare Inc 42.59%$ 42.588 millions
Laboratory Corporation Of America Holdings41.82%$ 41.815 millions
Livanova Plc41.44%$ 41.439 millions
Revance Therapeutics Inc 38.12%$ 38.121 millions
Entrada Therapeutics Inc 37.85%$ 37.853 millions
Beigene ltd 37.54%$ 37.536 millions
Inari Medical Inc 34.98%$ 34.983 millions
Henry Schein Inc34.48%$ 34.483 millions
Healthcare Services Group Inc 34.18%$ 34.176 millions
Veracyte inc 33.39%$ 33.387 millions
Haemonetics Corporation32.32%$ 32.324 millions
Steris Plc29.53%$ 29.533 millions
Organon and Co 28.57%$ 28.571 millions
Brookdale Senior Living Inc 26.22%$ 26.219 millions
Boston Scientific Corporation25.94%$ 25.943 millions
Lifemd Inc 25.16%$ 25.162 millions
Globus Medical Inc 24.76%$ 24.760 millions
Astrazeneca Plc24.75%$ 24.748 millions
Pro dex Inc 24.36%$ 24.361 millions
Abbott Laboratories23.77%$ 23.770 millions
Cel sci Corporation21.05%$ 21.054 millions
Avanos Medical Inc 20.41%$ 20.408 millions
National Vision Holdings Inc 19.62%$ 19.623 millions
Gilead Sciences Inc 18.78%$ 18.785 millions
Butterfly Network inc 18.38%$ 18.379 millions




Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com